Other substances

Sildenafil

A phosphodiesterase type 5 inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Other treatment

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Sildenafil on PubChem

Synonyms

Viagra

Marketed as

SILDENAFIL; REVATIO; VIZARSIN

CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors Small molecule In silico	in silico	4.29	Predicted to non-selectively bind bradykinin receptors, which was theorised to alleviate SARS-CoV-2-related inflammation.	Sep/21/2020

AI-suggested references

Link	Publication date
Sildenafil for treating patients with COVID-19 and perfusion mismatch: a pilot randomized trial.	Jan/03/2022
Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies	Mar/14/2022
Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease	Apr/08/2022
A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2.	Apr/03/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04489446	Sildenafil in COVID-19	Completed	Phase 1\|Phase 2	Aug/19/2020	Jun/30/2021
Alternative id - UNAB-003 Interventions - Drug: Sildenafil\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Hospital Naval Almirante Nef, Viña Del Mar, Valparaiso, Chile Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Arterial Oxygenation\|Alveolo-arterial gradient\|Intensive care unit admission\|Noninvasive Mechanical Ventilation or Requirement of High-Flow Nasal Cannula\|Invasive mechanical ventilation\|Survival
NCT04304313	A Pilot Study of Sildenafil in COVID-19	Unknown status	Phase 3	Feb/09/2020	Nov/09/2020
Alternative id - GST-G1 Interventions - Drug: Sildenafil citrate tablets Study type - Interventional Study results - No Results Available Locations - Department and Institute of Infectious Disease, Wuhan, Hubei, China Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 10 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Rate of disease remission\|Rate of entering the critical stage\|Time of entering the critical stage\|Rate of no fever\|Rate of respiratory symptom remission\|Rate of lung imaging recovery\|Rate of C-reactive protein (CRP) recovery\|Rate of Biochemical criterion (CK, ALT, Mb) recovery\|Rate of undetectable viral RNA (continuous twice)\|Time for hospitalization\|Rate of adverse event

Export (.csv)